1. c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays
- Author
-
Charpin-Taranger C, Claude Allasia, Charafe-Jauffret E, David Jérémie Birnbaum, Séverine Carpentier-Meunier, Jean-Philippe Dales, Pascal Bonnier, Lavaut Mn, Stéphane Garcia, Andrac-Meyer L, and Jocelyne Jacquemier
- Subjects
Cancer Research ,medicine.medical_specialty ,Pathology ,C-Met ,Immunocytochemistry ,Breast Neoplasms ,Biology ,chemistry.chemical_compound ,Automation ,Phosphatidylinositol 3-Kinases ,Breast cancer ,immunocytochemistry ,image analysis ,medicine ,skin and connective tissue diseases ,Molecular Diagnostics ,c-Met ,Tissue microarray ,tissue microarray ,Anatomical pathology ,Proto-Oncogene Proteins c-met ,medicine.disease ,Cadherins ,Immunohistochemistry ,Oncology ,chemistry ,Tissue Array Analysis ,Cancer research ,Breast carcinoma ,Inflammatory Breast Carcinoma - Abstract
Inflammatory breast carcinoma (IBC) is a rare but aggressive tumour associated with poor outcome owing to early metastases. Increased expression of c-Met protein correlates with reduced survival and high metastatic risk in human cancers including breast carcinomas and is targetable by specific drugs, that could potentially improve the prognosis. In the present study, we compared c-Met expression in IBC (n=41) and non-IBC (n=480) immunohistochemically (Ventana Benchmark autostainer) in two tissue microarrays (TMA) along with PI3K and E-cadherin. The results were quantified through an automated image analysis device (SAMBA Technologies). We observed that (i) c-Met was significantly overexpressed in IBC as compared with non-IBC (P
- Published
- 2007